Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
For specific cases, bariatric surgery may be an option if indicated
In the multicenter SURMOUNT trial, a 72-week treatment with tirzepatide, a dual GLP-1R/GIPR agonist, resulted in a 20.9% reduction in body weight17.7% greater than that observed in the placebo group
M., Presby, D
Research involving RETA focuses on understanding receptor interaction dynamics and system-level metabolic coordination in non-clinical research models
Exclusion criteria were inability to follow the study protocol and/or use of the following medications: digoxin, beta-receptor blockers, or calcium channel blockers
US$ 21.24
US$ 27.67
US$ 20.74
US$ 24.75
US$ 25.96
US$ 21.58
